# Sodium Tetradecyl Sulphate

## Fibro-Vein inj 3% 2mL \(專案進口\)

| 藥物代碼 | IFIB2 |
| :--- | :--- |
| 適應症 | For the treatment of uncomplicated primary varicose veins, recurrent or residual varicose veins following surgery, reticular veins, venules, and spider veins of the lower extremities that show simple dilation. |
| 副作用 | CommonDermatologic: Injection site pain, Injection site ulcer, Injection site urticariaGastrointestinal: Nausea, VomitingNeurologic: HeadacheSeriousCardiovascular: Myocardial infarctionDermatologic: Skin necrosis, Tissue necrosisHematologic: Arterial embolism, Deep venous thrombosisImmunologic: Allergic reaction, AnaphylaxisNeurologic: Cerebrovascular accidentRespiratory: Pulmonary embolism |
| 禁忌 | Hypersensitivity to sodium tetradecyl sulfate or to any component of the preparation and allergic conditions. Patients were unable to walk due to any cause, bedridden patients. Patients with a high risk of thrombosis e.g. patients with a congenital predisposition to blood clots or with multiple risk factors such as hormonal contraception or hormone replacement therapy, significant obesity, smoking, or extended periods of immobility. Recent acute superficial thrombophlebitis, deep vein thrombosis, or pulmonary embolism.Recent surgery. Varicosities caused by pelvic or abdominal tumors unless the tumor has been removed.Uncontrolled systemic disease such as diabetes mellitus, toxic hyperthyroidism, tuberculosis, asthma, neoplasm, sepsis, blood dyscrasias, and acute respiratory or skin diseases. Evolutive cancer. Significant valvular incompetence of the deep veins. Occlusive arterial disease. Huge superficial veins with wide open communications to deeper veins. Phlebitis migrans. Acute cellulitis. Acute infections. In addition when the sclerosant has been converted to foam: Known symptomatic patent foramen ovale \(PFO\). |
| 藥物保存方式 | 25°C以下 |
| 用法用量 | Because hypersensitivities have occurred, a test dose of 0.5 mL followed by several hours of observation is recommended before larger doses are administered. 0.5 to 2 mL \(preferably 1 mL MAX\) IV into the vein intended for sclerosis; the 1% solution is used most often, with the 3% solution being reserved for larger varicosities; MAX single treatment 10 mL. |
| 肝功能異常 | 無需調整劑量 |
| 腎功能異常 | 無需調整劑量 |
| 懷孕用藥危分級 | 尚未確立 |
| 孕期用藥建議 | N/A |
| 附帶說明 | \[仿單\]Safety for use in pregnancy has not been established. There are no or limited amount of data from the use of sodium tetradecyl sulfate in pregnant women. Animal studies are insufficient with respect to reproductive toxicity. Treatment should be postponed until after childbirth. Fibrovein should be used only when clearly needed for symptomatic relief and when the potential benefits outweigh the potential hazards to the fetus. |
| 哺乳期用藥建議 | Unknown 尚未建立 |
| 附帶說明 | \[仿單\] It is not known whether sodium tetradecyl sulfate is excreted in human milk. Caution should be exercised when used in nursing mothers. Fertility It is not known whether sodium tetradecyl sulfate affects fertility. |
| 注射劑給藥建議途徑 | N/A |
| 乾粉稀釋液 | N/A |
| 輸注點滴液 | N/A |
| IVP 用法建議 | N/A |
| IVD 用法建議 | N/A |
| 注意事項 | Fibrovein is a single-use parenteral product. Once the container is opened, use immediately and discard any unused portion. |

